Sanofi expands drug R&D activities in China
LONDON (Reuters) - France’s Sanofi-Aventis said on Tuesday it was expanding its research and development in presence in China, underlying a growing trend by global drug companies seeking to tap into the country’s science base.
Sanofi is expanding its R&D facility in Shanghai, establishing a new biometrics center in Beijing and has signed a partnership agreement with the Shanghai Institutes for Biological Sciences for the discovery of new drugs for neurological diseases, diabetes and cancer.
The expansion encompasses all stages of drug R&D, from drug-target identification to late-stage clinical studies.
Sanofi first established its R&D facility in Shanghai in June 2005, since when the unit has been involved in many clinical studies on medicines such as Lantus, rimonabant, Plavix, dronedarone and idrabiotaparinux.
The new biometrics center in Beijing will focus on study design, data management and statistical analysis of global and local clinical trials. It is planned to be fully operational by the end of the year.
(Reporting by Ben Hirschler)
--------------------------------------------------------------------------------------------Related Posts:
By Will Dunham WASHINGTON (Reuters) - About a quarter of biological medicines approved in the United States and Europe since 1995 have triggered safety warnings in the years after entering the market, Dutch researchers said on Tuesday. Immune system disorders, infusion reactions, infections and cancer concerns were among the reasons for safety warnings for biological medicines, which
Full Post: Many biological medicines draw safety warnings
--------------------------------------------------------------------------------------------
By Tan Ee Lyn HONG KONG (Reuters) - French drugmaker Sanofi-Aventis hopes to sell 25 million doses of seasonal flu vaccine annually into China’s largely untapped domestic market once its plant in the southern city of Shenzhen goes onstream in 2012. Wayne Pisano, head of the company’s vaccines arm Sanofi-Pasteur, said on Monday only two percent of
Full Post: Sanofi-Aventis to market seasonal flu vaccine in China
--------------------------------------------------------------------------------------------
By Bill Berkrot and Ransdell Pierson NEW ORLEANS (Reuters) - Sanofi-Aventis’s experimental drug Multaq significantly reduced the incidence of hospitalization and length of hospital stays in patients with atrial fibrillation, according to a new analysis of a previously reported study, researchers said on Tuesday. Multaq, known chemically as dronedarone, cut the total number of hospital days by
Full Post: Sanofi’s Multaq reduces hospitalization: study
--------------------------------------------------------------------------------------------
BEIJING (Reuters) - The United States is expanding a training program for Chinese health officials to include communications to promote transparency during disease outbreaks, the director of the U.S. Center for Disease Control said on Thursday. Southern China’s mix of densely populated cities, crowded wet markets, a relatively warm climate and close proximity of humans, poultry
Full Post: China to get U.S. training on handling outbreaks
--------------------------------------------------------------------------------------------
BOSTON (Reuters) - Bristol-Myers Squibb Co said on Tuesday it agreed to pay $1.1 million to settle charges connected with an anti-trust investigation by the New York State Attorney General’s Office, Last year, Bristol-Myers pleaded guilty to two federal criminal counts related to allegations that it illegally concealed a side deal with the generic drugmaker Apotex
Full Post: Bristol-Myers settles Plavix case with states